Champions Oncology reported a modest top-line rebound in Q4 2024, with revenue of $14.0 million, marking a 7% YoY increase and a 16.5% QoQ rise vs Q3 2024. The quarter delivered the first positive EBITDA in the period (adjusted EBITDA ≈ $0.9 million) and showed a meaningful gross-margin expansion to 49% for pharmacology services, contributing to a better gross margin profile that suggests improved operating leverage as the company right-sizes its operations after a difficult prior year. Management framed 2024 as a challenging year driven by external biotech funding weakness and internal execution headwinds, but signaled a gradual improving thesis as R&D budgets loosen and big-pharma engagements deepen. The company guided to a generally cash-neutral stance in fiscal 2025 with limited CapEx, reiterating a pathway toward profitability and revenue growth into the first half of 2025, aided by advancements in ex-vivo and core platforms and a renewed emphasis on tier-one pharma customers.